Covid-19 roundup: CureVac backs out of manufacturing contracts as demand dwindles; Despite PhII/III flop, biotech keeps looking for silver lining

Josh Sullivan

Amber Tong

CureVac terminated contracts with two companies who had signed on to help the German drug maker manufacture its mRNA Covid-19 vaccine in Europe, as potential …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: CureVac backs out of manufacturing contracts as demand dwindles; Despite PhII/III flop, biotech keeps looking for silver lining

Josh Sullivan

Amber Tong

Sign up to read this article for free.

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Covid-19 roundup: Cure­Vac backs out of man­u­fac­tur­ing con­tracts as de­mand dwin­dles; De­spite PhII/III flop, biotech keeps look­ing for sil­ver lin­ing

Sign up to read this article for free.

more like this

Covid-19 roundup: CureVac backs out of manufacturing contracts as demand dwindles; Despite PhII/III flop, biotech keeps looking for silver lining